Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity

Expert Review of Vaccines

Volumn 10, Issue 12, 2011, Pages 1709-1715

  Cassidy, Adrian ^a   Mossman, Sally ^a   Olivieri, Antonio ^a   Ridder, Marc De ^a,b   Leroux Roels, Geert ^c  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

effectiveness; genotype; hepatitis B; recombinant vaccine; vaccine

Indexed keywords

HEPATITIS B VACCINE;

BLOOD DONOR; DRUG EFFICACY; GENETIC VARIABILITY; GENOTYPE; HEALTH PROGRAM; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

GENETIC VARIATION; GENOTYPE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; VACCINATION; VACCINES, SYNTHETIC;

EID: 81355122722     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.151     Document Type: Review

References (56)

1. WHO. Hepatitis B vaccines: WHO position paper - recommendations. Vaccine 28, 589-590 (2010).
2. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int. J. Epidemiol. 34, 1329-1339 (2005). (Pubitemid 41819540)
3. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin. Infect. Dis. 20, 992-1000 (1995).
4. Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull. World Health Organ. 66, 443-455 (1988).
5. Expanded programme on immunization. Global advisory group - part I. Wkly Epidemiol. Rec. 67, 11-15 (1992).
6. Kane MA, Brooks A. New immunization initiatives and progress toward the global control of hepatitis B. Curr. Opin. Infect. Dis. 15, 465-469 (2002).
7. Arístegui J, Usonis V, Coovadia H et al. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Int. J. Infect. Dis. 7, 143-151 (2003). (Pubitemid 36753521)
8. WHO Department of Immunization, Vaccines and Biologicals. World Health Organization (WHO) vaccine-preventable diseases: monitoring system. 2009 global summary. WHO, Geneva, Switzerland (2009).
9. Hung HF, Chen THH. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and hepatitis B e antigen positive prevalence. Vaccine 27, 6770-6776 (2009).
10. MacIntyre CR. Hepatitis B vaccine: risks and benefits of universal neonatal vaccination. J. Paediatr. Child Health 37, 215-217 (2001).
11. Hollinger FB. Comprehensive control (or elimination) of hepatitis B virus transmission in the United States. Gut 38(Suppl. 2), S24-S30 (1996). (Pubitemid 26167501)
12. Krahn M, Detsky AS. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost- effectiveness analysis. Med. Decis. Making 13, 4-20 (1993). (Pubitemid 23019915)
13. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26, 6266-6273 (2008).
14. Purdy MA, Talekar G, Swenson P, Araujo A, Fields H. A new algorithm for deduction of hepatitis B surface antigen subtype determinants from the amino acid sequence. Intervirology 50, 45-51 (2007). (Pubitemid 46005271)
15. Okamoto H, Tsuda F, Sakugawa H et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J. Gen. Virol. 69, 2575-2583 (1988).
16. Hauser P, Voet P, Simoen E et al. Immunological properties of recombinant HBsAg produced in yeast. Postgrad. Med. J. 63(Suppl. 2), S83-S91 (1987).
17. Shokrgozar MA, Shokri F. Subtype specificity of anti-HBs antibodies produced by human B-cell lines isolated from normal individuals vaccinated with recombinant hepatitis B vaccine. Vaccine 20, 2215-2220 (2002). (Pubitemid 34497030)
18. Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. Hepatol. Res. 40, 14-30 (2010).
19. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin. Liver Dis. 14, 1-21 (2010).
20. Yu H, Yuan Q, Ge SX et al. Molecular and phylogenetic analyses suggest an additional hepatitis B virus genotype "I". PLoS One 5, e9297 (2010).
21. Jutavijittum P, Olinger C, Hubschen J, Yousukh A, Smountry B, Thammavong T. Molecular phylogeny of hepatitis B virus in Laos reveals multiple subtypes of endemic genotypes, numerous unclassifiable strains and a growing prevalence of recombinations within sub- and genotypes and a potential new genotype. Proceedings of the Molecular Biology of Hepatitis B Viruses. Rome, Italy, 16-20 September 2007.
22. Tran TTH, Trinh TN, Abe K. New complex recombinant genotype of hepatitis B virus identified in Vietnam. J. Virol. 82, 5657-5663 (2008). (Pubitemid 351705274)
23. Tatematsu K, Tanaka Y, Kurbanov F et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J. Virol. 83, 10538-10547 (2009).
24. Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J. Viral Hepat. 12, 456-464 (2005). (Pubitemid 41224248)
25. Stramer SL, Wend U, Candotti D et al. Nucleic acid testing to detect HBV infection in blood donors. N. Engl. J. Med. 364, 236-247 (2011).
26. Miller W. Serological assays. In: Hepatitis B Vaccines in Clinical Practice. Ellis RW, (Ed.). Marcel Dekker, NY, USA, 121-140 (1993).
27. Kim SH, Shin YW, Hong KW et al. Neutralization of hepatitis B virus (HBV) by human monoclonal antibody against HBV surface antigen (HBsAg) in chimpanzees. Antiviral Res. 79, 188-191 (2008).
28. Iwarson S, Tabor E, Thomas HC et al. Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: an experimental study in the chimpanzee. J. Med. Virol. 16, 89-96 (1985). (Pubitemid 15098392)
29. Schellekens H, de Reus A, Peetermans JH, van Eerd PA. The protection of chimpanzees against hepatitis B viral infection using a recombinant yeast-derived hepatitis B surface antigen. Postgrad. Med. J. 63(Suppl. 2), 93-96 (1987). (Pubitemid 17094406)
30. Chan C, Lee S, Lo K. Legend of hepatitis B vaccination: the Taiwan experience. J. Gastroenterol. Hepatol. 19, 121-126 (2004). (Pubitemid 38258336)
31. Wen WH, Chen HL, Ni YH et al. Secular trend of the viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization. Hepatology 53, 429-436 (2011).
32. Chang MH, You SL, Chen CJL et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl Cancer Inst. 101, 1348-1355 (2009).
33. Chen HL, Chang MH, Ni YH et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 276, 906-908 (1996).
34. Chongsrisawat V, Yoocharoen P, Theamboonlers AT et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop. Med. Int. Health 11, 1496-1502 (2006). (Pubitemid 44450554)
35. Wichajarn K, Kosalaraksa P, Wiangnon S. Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac. J. Cancer Prev. 9, 507-509 (2008).
36. Poovorawan Y, Chongsrisawat V, Theamboonlers A et al. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J. Viral Hepat. 18, 369-375 (2011).
37. Dong Y, Liu SL, Zhai XJ et al. A serological and molecular survey of hepatitis B in children 15 years after inception of the national hepatitis B vaccination program in eastern China. J. Med. Virol. 81, 1517-1524 (2009).
38. Liang X, Bi S, Yang W et al. Epidemiological serosurvey of hepatitis B in China - declining HBV prevalence due to hepatitis B vaccination. Vaccine 27, 6550-6557 (2009).
39. Liang X, Bi S, Yang W et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J. Infect. Dis. 200, 39-47 (2009).
40. Viviani S, Jack A, Hall AJ et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 17, 2946-2950 (1999). (Pubitemid 29366973)
41. Kimbi GC, Kramvis A, Kew MC. Distinctive sequence characteristics of subgenotype A1 isolates of hepatitis B virus from South Africa. J. Gen. Virol. 85, 1211-1220 (2004). (Pubitemid 38659784)
42. Bhimma R, Coovadia HM, Adhikari M, Connolly CA. The impact of the hepatitis B virus vaccine on the incidence of hepatitis B virus-associated membranous nephropathy. Arch. Pediatr. Adolesc. Med. 157, 1025-1030 (2003). (Pubitemid 37222100)
43. Tacke F, Amini-Bavil-Olyaee S, Heim A, Luedde T, Manns MP, Trautwein C. Acute hepatitis B virus infection by genotype F despite successful vaccination in an immune-competent German patient. J. Clin. Virol. 38, 353-357 (2007). (Pubitemid 46414002)
44. O'Halloran JA, De Gascun CF, Dunford L et al. Hepatitis B virus vaccine failure resulting in chronic hepatitis B infection. J. Clin. Virol. 52(2), 151-154 (2011).
45. Ramírez Albajés V, González Griego A, Almeida Varela R et al. Effectividad absoluta y relativa de la vacunación antihepatitis B en niños de quillabamba, perú, 1997-1999. Rev. Cubana. Invest. Biomed. 19, 82-88 (2000).
46. Duarte MC, Cardona N, Poblete F et al. A comparative epidemiological study of hepatitis B and hepatitis D virus infections in Yanomami and Piaroa Amerindians of Amazonas State, Venezuela. Trop. Med. Int. Health 15, 924-933 (2010).
47. Nunes HM, Monteiro MR, Soares M do CP. [Prevalence of hepatitis B and D serological markers in the Parakanã, Apyterewa Indian Reservation, Pará State, Brazil.] Cad. Saude Publica 23, 2756-2766 (2007).
48. Venegas M, Alvarado-Mora MV, Villanueva RA et al. Phylogenetic analysis of hepatitis B virus genotype F complete genome sequences from Chilean patients with chronic infection. J. Med. Virol. 83, 1530-1536 (2011).
49. McMahon BJ, Bulkow LR, Singleton RJ et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology doi:10.1002/hep.24442 (2011) (Epub ahead of print).
50. Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill. Summ. 58, 1-27 (2009).
51. Inui A, Komatsu H, Sogo T, Nagai T, Ade K, Fujisawa T. Hepatitis B virus genotypes in children and adolescents in Japan: before and after immunization for the prevention of mother to infant transmission of Hepatitis B virus. J. Med. Virol. 79, 670-675 (2007). (Pubitemid 46709360)
52. Yu MW, Yeh SH, Chen PJ et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J. Natl Cancer Inst. 97, 265-272 (2005).
53. Ocana S, Casas ML, Buhigas I, Lledo JL. Diagnostic strategy for occult hepatitis B virus infection. World J. Gastroenterol. 17, 1553-1557 (2011).
54. Gutiérrez-García ML, Fernandez- Rodriguez CM, Lledo-Navarro JL, Buhigas-Garcia I. Prevalence of occult hepatitis B virus infection. World J. Gastroenterol. 17, 1538-1542 (2011).
55. Romero M, Madejón A, Fernández- Rodríguez C, García-Samaniego J. Clinical significance of occult hepatitis B virus infection. World J. Gastroenterol. 17, 1549-1552 (2011).
56. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 43, 721-729 (2003). (Pubitemid 36629116)